Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

Bladder Cancer Clinical Trial

Official title:

A Phase 2, Single-Arm Study of Pralatrexate in Patients With Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00722553
• Other study ID #: PDX-011
• Secondary ID: 2007-004671-19
• Status: Completed
• Phase: Phase 2
• Start date: July 2008
• Est. completion date: September 2011

Study information

• Verified date: December 2019
• Source: Acrotech Biopharma LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether pralatrexate, given with vitamin B12 and folic acid, is effective in the treatment of advanced or metastatic bladder cancer. The study will also investigate the safety of pralatrexate with vitamin B12 and folic acid in this patient population. Additionally, this study includes the collection of blood samples to investigate the pharmacokinetics (PK) of pralatrexate in this patient population (PK is the activity of a drug in the body over a period of time, including how the drug is absorbed, distributed in the body, localized in the tissues, and excreted from the body).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: September 2011
• Est. primary completion date: April 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed transitional cell carcinoma of the urinary bladder. Fine needle aspirate will not be accepted.

• Relapsed or progressed after treatment with a platinum- and/or methotrexate-based systemic chemotherapy regimen. No more than 1 prior regimen is permitted for recurrent/metastatic disease. Patients has had a chemotherapy-free interval of = 12 months from last dose if most recent prior chemotherapy was in neoadjuvant/adjuvant setting and has had = 6-month chemotherapy-free interval in recurrent/metastatic setting. Patient has recovered from the toxic effects of prior therapy. Previous intravesical therapy is allowed. Prior surgical resection is allowed, as long as the patient has recovered.

• Measurable disease outside a previously irradiated region, per Response Evaluation Criteria in Solid Tumors (RECIST).

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• At least 18 years of age.

• Adequate blood, liver, and kidney function as defined by laboratory results.

• Patient has received 1.0-1.25 mg of oral folic acid daily for at least 7 days of enrollment & 1 mg intramuscular vitamin B12 within 10 weeks of enrollment.

• Women of childbearing potential have a negative serum pregnancy test within 14 days prior to enrollment and agree to use medically acceptable and effective birth control from enrollment until at least 30 days after the last dose of pralatrexate.

• Men who are not surgically sterile and whose partner is of childbearing potential must use medically safe and effective birth control start of pralatrexate until at least 90 days after the last dose of pralatrexate.

• Accessible for repeat dosing and follow up.

• Give written informed consent.

Exclusion Criteria:

• Active concurrent primary malignancy or prior malignancies occurring within 5 years (except non-melanoma skin cancer, in situ carcinoma of the cervix, or occult, indolent carcinoma of the prostate). If there is a history of prior malignancies other than those exceptions listed above, the patient must be disease free for = 5 years. Patients with other prior malignancies < 5 years before study entry may still be enrolled if they have received treatment resulting in complete resolution of the cancer and currently have no clinical, radiologic, or laboratory evidence of active or recurrent disease. In the case of a single extrapelvic metastatic site, irrespective of the patient having a history of previous malignancy, a biopsy proof of the metastatic diseased organ will be necessary.

• More than 1 previous regimen for recurrent/metastatic disease.

• Evidence of clinically significant active third-space phenomenon

• Use of investigational drugs, biologics, or devices within 28 days prior to study enrollment.

• Previous exposure to other antifolates, including pralatrexate. Previous methotrexate is allowed, only if it was part of an M-VAC or MCV regimen.

• Women who are pregnant or breastfeeding.

• Congestive Heart Failure Class III/IV according to New York Heart Association (NYHA) Functional Classification.

• Uncontrolled hypertension.

• Human immunodeficiency virus (HIV)-positive diagnosis with a CD4 count of < 100 mm3 or detectable viral load within the past 3 months, and receiving combination anti-retroviral therapy.

• Central nervous system metastatic disease.

• Major surgery within 2 weeks of study enrollment.

• Radiation therapy (RT) within 4 weeks (within 3 months for RT to the pelvis) prior to study enrollment.

• Active infection or any serious underlying medical condition, which would impair the ability of the patient to receive protocol treatment.

• Dementia or significantly altered mental status that would prohibit the understanding and giving of informed consent or limit study compliance.

Related Conditions & MeSH terms

• Bladder Cancer
• Bladder Neoplasm
• Carcinoma
• Carcinoma, Transitional Cell
• Urinary Bladder Neoplasms

Intervention

Drug:
• Pralatrexate Injection
Intravenous (IV) push administration over 3-5 minutes via a peripheral IV line containing normal saline (0.9% sodium chloride). Initial dose: 190 mg/m2 Dose reductions per protocol: 150 mg/m2, 120 mg/m2 and 100 mg/m2 will be allowed for defined toxicity. Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met.

Dietary Supplement:
• Vitamin B12
1 mg intramuscular injection Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate.
• Folic Acid
1-1.25 mg orally Administered daily for at least 7 days prior to enrollment, throughout the study and for at least 30 days after last dose of pralatrexate.

Locations

Country	Name	City	State
Argentina	IONC (Instituto Oncológuci de Cordoba)	Cordoba
Argentina	Centro de Terapia Radiante Cumbres (CAICI)	Rosario	Santa Fe
Belgium	Algemeen Ziekenhuis Middelheim	Antwerp
Belgium	Institut Jules Bordet	Brussels
Croatia	CH Split Clinic of Oncology and Radiotherapy	Split
Croatia	CHU Zagreb University Hospital Center Rebro in Zagreb	Zagreb
Croatia	Clinic of Oncology and Nuclear Medicine, CH "Sestre Milosrdnice"	Zagreb
France	Institut Sainte Catherine	Avignon
France	Centre Oscar Lambret	Lille Cedex
France	Centre Hospitalier Rene Dubos	Pontoise
France	Hopital Foch	Suresnes
France	Institut Gustave Roussy	Villejuif Cedex
Spain	Ciutat Sanitari de Vall d'Hebron	Barcelona
Spain	Hospital Del Mar - Barcelona	Barcelona
Spain	Hospital Virgen del Rocio	Sevilla
United States	Peachtree Hematology/Oncology Consultants	Atlanta	Georgia
United States	University of Rochester Cancer Center	Rochester	New York
United States	University of Utah, Huntsman Cancer Institute	Salt Lake City	Utah
United States	The University of Arizona Health Sciences Center	Tucson	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Acrotech Biopharma LLC

Countries where clinical trial is conducted

United States,  Argentina,  Belgium,  Croatia,  France,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate (ORR)	The number of patients with a best overall confirmed response of either complete response (CR) or partial response (PR)	Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but no more than every 12 weeks (+/- 1 week) if treatment has ended for up to 2 years after enrollment.
Secondary	Duration of Response (DOR)	Duration of time from when tumor measurement criteria were met for CR or PR (whichever status was recorded first) until the first date that recurrent disease or progressive disease (PD) or death was objectively documented. Progression is defined, using RECIST, as an increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline. Calculated for those patients with a best overall confirmed or unconfirmed response of CR or PR.	Measured from the first day of documented response for up to 2 years after enrollment.
Secondary	Clinical Benefit Rate (CBR)	The number of patients with a best confirmed or unconfirmed response of CR, PR, or stable disease (SD) for at least 24 weeks (approximately 5.5 months)	Assessed at the end of each even-numbered cycle (every 8 weeks) or per standard of care, but no more than every 12 weeks (+/- 1 week) if treatment has ended, for up to 2 years after enrollment.
Secondary	Progression Free Survival (PFS)	Length of time from study day 1 to the date of radiological evidence of PD (date of computed tomography [CT] or magnetic resonance imaging [MRI] scan, whichever indicates PD) or death, regardless of cause.	Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but no more than every 12 weeks (+/- 1 week) if treatment has ended, for up to 2 years after enrollment.
Secondary	Overall Survival (OS)	The number of days from study day 1 to death. Patients who had not died (no record of death) or were lost to follow-up were censored at the date of last contact.	Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care if treatment has ended (at least every 12 weeks) for up to 2 years after enrollment. After PD or start of subsequent treatment, OS will be assessed every 4 months.